Novel Therapeutic Approach to Invasive Group A Streptococcal Disease
Novel Therapeutic Approach to Invasive Group A Streptococcal Disease
批准号:
10546470
负责人:
Michael G. Caparon
金额:
$19.56万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-01-05 至 2024-12-31
关键词:
AccelerationAcidsAddressAdoptive TransferAerobicAnimal ModelAnti-Inflammatory AgentsAntibiotic TherapyAntibioticsBacteriaBehaviorCellsCirculationDataDebridementDiseaseDisease OutcomeEndosomesEnzymesEquilibriumFermentationGenerationsGeneticGoalsGram-Positive BacteriaGrowthHourImmuneImmune responseImmunosuppressionIn VitroInfectionInfectious Skin DiseasesInflammatoryInterleukin-10Lactate DehydrogenaseLesionMacrophageMediatorMetabolicMetabolic PathwayMetabolismModelingMusNecrotizing fasciitisOperative Surgical ProceduresOxygenPathogenesisPathologyPathway interactionsPerfusionPhenocopyPlayProcessProductionPyruvatePyruvate Metabolism PathwayRoleSeverity of illnessSignal PathwaySignal TransductionSiteSoft Tissue InfectionsStreptococcusStreptococcus pyogenesTestingTherapeuticTherapeutic InterventionTissuesTreatment outcomeUlcerValidationVolatile Fatty Acidsarmattenuationcytokinedisorder controlfatty acid metabolismimprovedin vivoinhibitorlactic acid bacterialimb amputationmicrobialmortalitymutantnovel strategiesnovel therapeutic interventionpathogenpharmacologicpreventpyruvate dehydrogenaserecruitresponsesingle-cell RNA sequencingstandard of caresubcutaneous
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Microbial-derived Short Chain Fatty Acids (SCFAs) have emerged as important mediators of
“Disease Tolerance,” a process that seeks to limit collateral damage to host tissues that
accompanies immune responses. SCFAs are the principle end-products of the metabolism of the
Gram-positive pathogen Streptococcus pyogenes which can cause several severe invasive
diseases that are notoriously difficult to treat due to extensive and rapid tissue destruction that
limits perfusion of antibiotics to the site of bacterial multiplication. For the most severe
manifestations, in particular necrotizing fasciitis, lesions expand to involve additional tissue at a
rapid rate that can approach several cm per hour. This necessitates multiple rounds of aggressive
and disfiguring surgical interventions, including debridement, fasciotomy and even amputation of
limbs and this lack of therapeutic options results in high mortality. An important gap in our
treatment arsenal is the lack of therapies to mitigate tissue damage during severe invasive
disease, which would improve the efficacy of antibiotic treatment to promote clearance of the
infection. The goal of this study is to explore proof-of-principle that therapeutic manipulation of
streptococcal pyruvate metabolism can provide a viable strategy for mitigation of tissue damage
to improve treatment outcomes of severe, invasive S. pyogenes disease. This concept builds
upon our preliminary data that suggests S. pyogenes employs its several alternative pathways for
pyruvate reduction to actively manipulate the host’s “Disease Tolerance” response to promote
its ability to infect diverse host niches. Disease tolerance is the process the host employs to
balance pathogen growth against the collateral damage to host tissues that accompanies immune
responses, known as Growth/Damage Balance. Through identification of host cells and relevant
signaling pathways that control disease tolerance, a therapeutic approach that targets microbial
metabolic and host cell signaling pathways can reduce damage to tissue to improve the ability of
antibiotics to clear infections.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Central carbon flux controls growth/damage balance for Streptococcus pyogenes.
中央碳通量控制化脓链球菌的生长/损害平衡。
DOI:
10.1371/journal.ppat.1011481
发表时间:
2023-06
期刊:
PLoS pathogens
影响因子:
6.7
作者:
[]
通讯作者:
Novel Therapeutic Approach to Invasive Group A Streptococcal Disease
-
批准号:10452033
-
项目类别:
-
资助金额:$23.63万
-
财政年份:2022
-
负责人:Michael G. Caparon
-
依托单位:
Characterization of assembly factors for type IV secretion systems
-
批准号:10435561
-
项目类别:
-
资助金额:$25.42万
-
财政年份:2021
-
负责人:Michael G. Caparon
-
依托单位:
GmPcides: Componds that disarm antibiotic resistance in multiple gram-positive pathogens
-
批准号:10577811
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2021
-
负责人:Michael G. Caparon
-
依托单位:
GmPcides: Componds that disarm antibiotic resistance in multiple gram-positive pathogens
-
批准号:10162829
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2021
-
负责人:Michael G. Caparon
-
依托单位:
GmPcides: Componds that disarm antibiotic resistance in multiple gram-positive pathogens
-
批准号:10352471
-
项目类别:
-
资助金额:$36.09万
-
财政年份:2021
-
负责人:Michael G. Caparon
-
依托单位:
Structure-function analysis of type IVB secretion systems
-
批准号:10624264
-
项目类别:
-
资助金额:$51.18万
-
财政年份:2019
-
负责人:Michael G. Caparon
-
依托单位:
EBPA-FIBROGEN INTERACTION IN ENTEROCOCCUS FAECALIS CAUTI
-
批准号:9304949
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2014
-
负责人:Michael G. Caparon
-
依托单位:
EBPA-FIBROGEN INTERACTION IN ENTEROCOCCUS FAECALIS CAUTI
-
批准号:8759401
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2014
-
负责人:Michael G. Caparon
-
依托单位:
EBPA-FIBROGEN INTERACTION IN ENTEROCOCCUS FAECALIS CAUTI
-
批准号:8901925
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2014
-
负责人:Michael G. Caparon
-
依托单位:
CATABOLITE REPRESSION CONTROLS VIRULENCE IN STREPTOCOCCUS PYOGENES
-
批准号:9174072
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2007
-
负责人:Michael G. Caparon
-
依托单位:
Novel Catabolite Repression Pathway Controls Virulence in Streptococcus pyogenes
-
批准号:8084162
-
项目类别:
-
资助金额:$32.88万
-
财政年份:2007
-
负责人:Michael G. Caparon
-
依托单位:
CATABOLITE REPRESSION CONTROLS VIRULENCE IN STREPTOCOCCUS PYOGENES
-
批准号:8974235
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2007
-
负责人:Michael G. Caparon
-
依托单位:
CATABOLITE REPRESSION CONTROLS VIRULENCE IN STREPTOCOCCUS PYOGENES
-
批准号:8629130
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2007
-
负责人:Michael G. Caparon
-
依托单位:
Novel Catabolite Repression Pathway Controls Virulence in Streptococcus pyogenes
-
批准号:7454315
-
项目类别:
-
资助金额:$33.55万
-
财政年份:2007
-
负责人:Michael G. Caparon
-
依托单位:
Novel Catabolite Repression Pathway Controls Virulence in Streptococcus pyogenes
-
批准号:7318097
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2007
-
负责人:Michael G. Caparon
-
依托单位:
Short Chain Fatty Acids and Streptococcus Pyogenes Virulence
-
批准号:9982473
-
项目类别:
-
资助金额:$35.33万
-
财政年份:2007
-
负责人:Michael G. Caparon
-
依托单位:
Novel Catabolite Repression Pathway Controls Virulence in Streptococcus pyogenes
-
批准号:7640841
-
项目类别:
-
资助金额:$33.55万
-
财政年份:2007
-
负责人:Michael G. Caparon
-
依托单位:
Novel Catabolite Repression Pathway Controls Virulence in Streptococcus pyogenes
-
批准号:7880576
-
项目类别:
-
资助金额:$33.21万
-
财政年份:2007
-
负责人:Michael G. Caparon
-
依托单位:
CYTOLYSIN-MEDIATED TRANSLOCATION IN S. PYOGENES VIRULENC
-
批准号:8417693
-
项目类别:
-
资助金额:$31.83万
-
财政年份:2005
-
负责人:Michael G. Caparon
-
依托单位:
Cytolysin-mediated translocation in S.pyogenes virulence
-
批准号:7558997
-
项目类别:
-
资助金额:$32.02万
-
财政年份:2005
-
负责人:Michael G. Caparon
-
依托单位:
国内基金
海外基金
登录
查看更多内容
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
-
批准号:22007039
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:王黎明
-
依托单位:
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:朱义广
-
依托单位:
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
-
批准号:21372217
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:袁伟成
-
依托单位:
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
-
批准号:21172061
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2011
-
负责人:许新华
-
依托单位:
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
-
批准号:21176225
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:童少平
-
依托单位:
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
-
批准号:81072511
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2010
-
负责人:严江伟
-
依托单位:
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
-
批准号:30660215
-
项目类别:地区科学基金项目
-
资助金额:21.0万元
-
批准年份:2006
-
负责人:王世范
-
依托单位: